[
  {
    "criterion": "Provides a clear and concise overview of the benefits of blocking IL-13 and IL-31 for severe atopic dermatitis.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Mentions the limitations of relying on either IL-13 or IL-31 blocking for complete remission or full cessation of flares.",
    "axis": "completeness",
    "point": 6
  },
  {
    "criterion": "Correctly explains that both IL-13 and IL-31 blocking can be beneficial for severe atopic dermatitis.",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Fails to mention any potential side effects or risks associated with IL-13 and IL-31 blocking.",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Uses overly technical language or jargon that may be difficult for a non-expert to understand.",
    "axis": "communication_quality",
    "point": -3
  },
  {
    "criterion": "Correctly incorporates the user's original text with minimal changes for clarity.",
    "axis": "communication_quality",
    "point": 5
  },
  {
    "criterion": "Does not address the user's request to keep the original text with minimal changes.",
    "axis": "context_awareness",
    "point": -2
  },
  {
    "criterion": "Provides additional context or information from the past year without changing the original meaning.",
    "axis": "completeness",
    "point": 4
  },
  {
    "criterion": "Fails to provide any additional context or information from the past year.",
    "axis": "completeness",
    "point": -2
  },
  {
    "criterion": "Correctly phrases the original text for sharing with the immunology team.",
    "axis": "communication_quality",
    "point": 6
  }
]